Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.endonu.2014.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reduction of Ovarian Cysts After Endoscopic Surgery for Follicle-Stimulating Hormone-Producing Pituitary Adenoma.
JCEM Case Rep
December 2024
Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Yamanashi 4093898, Japan.
A 49-year-old woman presented with irregular menstrual bleeding, elevated estradiol (E2) (665 pg/mL [2441.21 pmol/L]) (reference range [RR]: menstrual period [MP] 20-50 pg/mL; 73.42-183.
View Article and Find Full Text PDFHidden identities in plurihormonal pituitary neuroendocrine tumours: expanding the spectrum of the 'silent corticogonadotroph adenoma'.
Pathology
November 2024
Department of Neuropathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney, Sydney, NSW, Australia. Electronic address:
Multilineage Pituitary Neuroendocrine Tumors Expressing TPIT and SF1: A Clinicopathological Series of Six Tumors.
Endocr Pathol
December 2024
Derpartment of Pathology, Department of Laboratory Medicine and Pathology, University Health Network, University of Toronto, Toronto, ON, M5G2C4, Canada.
Tumors of adenohypophysial hormone-secreting cells, now classified as pituitary neuroendocrine tumors (PitNETs), have been subclassified based on cell differentiation. Normal adenohypophysial cells have three lineages of differentiation driven by the transcription factors PIT1, TPIT, and SF1 which are responsible for the regulation of hormone gene expression; PIT1 drives expression of GH, PRL, and TSH, TPIT is required for POMC expression that gives rise to ACTH, and SF1 is the transcription factor responsible for FSH and LH expression. The vast majority of PitNETs follow these three lineage differentiation pathways but rare PitNETs show either no lineage differentiation or express biomarkers of more than one lineage.
View Article and Find Full Text PDFTypical morphological characteristics of the immunohistochemical subtypes of pituitary microadenomas: a dual center study.
Endocr Connect
December 2024
Department of Neurosurgery, Nanyang Central Hospital, Nanyang, Henan, China.
Purpose: This study aimed to investigate the relationship between magnetic resonance image (MRI) features and the immunohistochemical subtypes of pituitary microadenomas (PMAs) characterized by location and growth pattern.
Materials And Methods: A double-center, retrospective review of MRI characteristics was conducted in 57 PMA cases recorded from February 2014 to September 2023, identified based on the 2017 World Health Organization classification of pituitary gland tumors. The geometric center of the tumor was defined, and the possibility of PMA vertical or lateral growth patterns was evaluated according to the ratio of maximum diameter between the X and Y axes.
PCSK1N as a tumor size marker and an ER stress response protein in corticotroph pituitary adenomas.
J Clin Endocrinol Metab
September 2024
Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS) Oslo, Norway.
Purpose: Silent corticotroph adenoma (SCA) exhibits more tumor aggressiveness features than functioning adenomas (FCA). We aimed to investigate PCSK1N expression in CA and examine if ER stress-induced responses affect cell survival in a corticotroph tumor cell model.
Methods: Clinical and imaging characteristics were recorded in 33 patients with FCA (20 women, 11 macroadenomas) and 18 SCA (8 women, all macroadenomas).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!